PDCD1LG2 and hepatocellular carcinoma: In addition, this study has provided potentially practical management options for future clinical trials on anti PD-1 axis therapy for HCC patients, it should be based on the expression of PD-L1, PD-L2, and CD8 along with the clinicopathological characteristics of HCC patients.